focus -WSS

focus

author：explore 2025-09-28 01:16:37 - browse：4454

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Medicare Advantage enrollment grows 7.1% to 33.4 million people

WSS

Flagship Pioneering startup Sonata Therapeutics lays off 21

Weight bias in eating disorder treatment complicated by new weight loss drugs

Measles policy set amid Florida outbreak alarms vaccine proponents

CDC concerned about possible undetected monkeypox spread in U.K.

The strategy behind pharma's lawsuits over drug pricing reform

Cloning humans is technically possible. It's curious no one has tried

leisure time

focus

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

In 'major milestone,' FDA approves first cell therapy for solid tumors

Trump demands the U.S. pay no more for drugs than other countries … again

Paxlovid study fails to answer questions over benefit for broader groups

Tori Bowie and the unacceptable rates of Black maternal death

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Alkermes shareholders re

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Moonlake's readout produced a cash windfall. Risks remain

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Wikipedia

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Surprise medical billing ban raises prices elsewhere

Why we need to separate burnout from moral injury in health care

MD Anderson's Padmanee Sharma responds to research credit suit

Hospitals are piloting generative AI tools as regulators play catch

Donald Trump's relentless attacks on special counsel Jack Smith

knowledge

hotspot

focus

focus